Pi3K Akt Signaling In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling axis is one of the most critical pro-survival pathways in the central nervous system, governing neuronal growth, differentiation, synaptic plasticity, metabolism, and resistance to apoptosis. Downstream of insulin receptors, receptor tyrosine kinases (TrkA/B/C), and G-protein-coupled receptors, the PI3K/Akt cascade phosphorylates and regulates a network of substrates — including GSK-3β, mTOR, FOXO transcription factors, BAD, and caspase-9 — that collectively determine whether a neuron survives or enters apoptotic programs [1].
Impaired PI3K/Akt signaling is a convergent pathological feature of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and
Frontotemporal Dementia (FTD). In Alzheimer's Disease, this pathway has attracted intense interest due to its intimate connection with brain insulin resistance — sometimes
described as "type 3 diabetes" — in which deficient insulin/IGF-1 signaling through PI3K/Akt leads to GSK-3β hyperactivation, tau] hyperphosphorylation],
impaired autophagy, and reduced neuronal glucose metabolism [2]. Understanding the stage-dependent behavior of this pathway —
neuroprotective when appropriately activated, potentially harmful when chronically dysregulated — is essential for developing effective therapeutic strategies.
¶ Pathway Components and Signaling Architecture
Class I PI3Ks are heterodimeric lipid kinases consisting of a catalytic subunit (p110α, p110β, p110δ, or p110γ) and a regulatory subunit (p85α, p85β, p55γ, or p101). Upon receptor activation, PI3K is recruited to the plasma membrane where it phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3) — the key lipid second messenger that recruits Akt and PDK1 to the membrane [3].
In the brain, PI3K signaling is activated by:
- Insulin and IGF-1 receptors: Critical for neuronal glucose metabolism, synaptic plasticity, and survival. Insulin receptor substrate 1 (IRS-1 and IRS-2 couple insulin receptors to PI3K
- Neurotrophin receptors: BDNF/TrkB, GDNF/Ret, and NGF/TrkA activate PI3K to promote neuronal survival and differentiation
- Integrin signaling: Cell-matrix interactions activate PI3K through focal adhesion kinase (FAK)
- GPCR signaling: Class I_B PI3Kγ (p110γ/p101) is activated by Gβγ subunits, particularly relevant in microglia | Thr1462 | Activation of mTOR | Stimulates protein synthesis; inhibits autophagy; impairs Aβ/tau] clearance |
| FOXO1/3a | Thr24/Ser256 | Nuclear exclusion | Loss of Akt → FOXO nuclear entry → expression of pro-apoptotic genes (Bim, FasL) |
| BAD | Ser136 | Inactivation (pro-survival) | Unphosphorylated BAD sequesters Bcl-xL → apoptosis |
| Caspase-9 | Ser196 | Inactivation | Direct anti-apoptotic effect |
| IKKα | Thr23 | NF-κB activation | Context-dependent: survival vs. neuroinflammation |
| AS160/TBC1D4 | Thr642 | GLUT4 translocation | Impaired neuronal glucose uptake in AD |
The most extensively characterized connection between PI3K/Akt and neurodegeneration is in Alzheimer's Disease, where brain insulin resistance creates a vicious cycle of metabolic failure:
IRS-1 serine phosphorylation: In AD brain, IRS-1 is excessively phosphorylated at inhibitory serine residues (Ser312, Ser616, Ser636) by JNK, IKK, and mTOR/S6K1 — the same modifications seen in peripheral insulin resistance. This uncouples insulin receptors from downstream PI3K activation, creating a state of central insulin resistance [4].
Aβ oligomers impair insulin signaling: Soluble [Aβ oligomers/proteins/amyloid directly compete with insulin for binding to insulin receptors and activate the TNF-α/JNK pathway that promotes inhibitory IRS-1 phosphorylation. This creates a feed-forward loop: Aβ → insulin resistance → GSK-3β activation → more Aβ production and tau phosphorylation [5].
GSK-3β hyperactivation: Without Akt-mediated inhibitory phosphorylation at Ser9, GSK-3β becomes constitutively active, phosphorylating tau/proteins/tau at AD-relevant epitopes (Thr181, Ser202, Thr231, Ser396, Ser404), promoting neurofibrillary tangle formation. GSK-3β also phosphorylates presenilin-1, enhancing γ-secretase activity and Aβ42 production [6].
Stage-dependent mTOR dynamics: At early disease stages, the PI3K/Akt signaling axis is suppressed, which decreases mTOR kinase activity and activates autophagy flux as a compensatory response. However, as Aβ accumulates, aberrant mTORC1 hyperactivation occurs in some neuronal populations, suppressing autophagy and impairing clearance of protein aggregates. At advanced disease stages, accumulated autophagosomes may propagate apoptotic signals [7].
Glucose hypometabolism: Reduced PI3K/Akt signaling impairs GLUT3/4 translocation to the neuronal membrane, contributing to the characteristic FDG-PET hypometabolism pattern in AD [temporoparietal cortex]. This metabolic deficit may precede clinical symptoms by 10-20 years [8].
In Parkinson's Disease, PI3K/Akt signaling intersects with multiple disease mechanisms:
- LRRK2: Gain-of-function mutations in LRRK2 (G2019S) suppress Akt signaling through enhanced phosphorylation of PTEN, reducing neuronal survival capacity
- α-Synuclein: [alpha-synuclein/proteins/alpha oligomers activate PP2A, which dephosphorylates and inactivates Akt. Conversely, Akt phosphorylates α-synuclein at Ser129, modulating its aggregation propensity
- PINK1/Parkin: The PINK1/proteins/pink1/Parkin mitophagy pathway is regulated by Akt at multiple nodes. Akt phosphorylates PINK1, modulating its kinase activity, while Parkin ubiquitination is influenced by Akt-dependent signaling
- Astrocyte-microglial disparities: PI3K/Akt signaling shows cell-type-specific effects: activation in astrocytes is anti-inflammatory, while in [microglia/cell-types/microglia it can promote either M1 (inflammatory) or M2 (resolving) polarization depending on context [9]
[Mutant huntingtin/proteins/huntingtin) disrupts PI3K/Akt signaling through multiple mechanisms:
- Sequestration of IRS-2 in huntingtin aggregates reduces insulin/IGF-1 signaling
- Akt directly phosphorylates huntingtin at Ser421, and this phosphorylation is neuroprotective by reducing mutant huntingtin toxicity and cleavage. Akt activity declines with disease progression
- Reduced BDNF transport from cortex to striatum decreases TrkB→PI3K→Akt signaling in vulnerable [medium spiny neurons/cell-types/medium-spiny-neurons
PI3K/Akt signaling is compromised in ALS motor neurons:
- Mutant [SOD1/proteins/sod1 activates PTEN, reducing PIP3 levels and Akt phosphorylation
- TDP-43 aggregation disrupts mRNA processing of PI3K pathway components
- IGF-1 delivery has shown modest neuroprotection in preclinical ALS models, supporting the therapeutic relevance of this pathway
The regulation of autophagy by the PI3K/Akt/mTOR axis is of critical importance in neurodegeneration because all major neurodegenerative diseases feature accumulation of misfolded protein aggregates that must be cleared by autophagic mechanisms:
mTOR complex 1 (mTORC1) is the central negative regulator of autophagy. When active, mTORC1:
- Phosphorylates ULK1 at Ser757, preventing ULK1/Atg13/FIP200 complex formation and autophagosome nucleation
- Phosphorylates TFEB at Ser211, sequestering it in the cytoplasm via 14-3-3 binding, preventing transcription of lysosomal and autophagy genes
- Phosphorylates ATG14L, inhibiting the VPS34 complex that generates PI3P for autophagosome membrane expansion
When PI3K/Akt/mTORC1 is inhibited (by nutrient deprivation, rapamycin, or reduced insulin signaling), autophagy is induced, promoting clearance of [Aβ/proteins/amyloid, tau/proteins/tau, [α-synuclein/proteins/alpha, and huntingtin aggregates [10].
This creates a fundamental therapeutic dilemma:
- Activating PI3K/Akt promotes neuronal survival, inhibits GSK-3β-mediated tau phosphorylation, and prevents apoptosis — but also activates mTORC1 and suppresses autophagy
- Inhibiting PI3K/Akt/mTOR induces autophagy and enhances protein aggregate clearance — but removes pro-survival signaling and may activate GSK-3β
Resolving this paradox may require targeting specific nodes:
- Activating Akt while separately inhibiting mTORC1 (e.g., Akt activators + rapamycin analogs)
- Targeting TFEB directly to induce lysosomal biogenesis without suppressing Akt
- Using AMPK activators (metformin) to inhibit mTORC1 while leaving Akt signaling intact [11]
¶ Insulin Sensitizers and Intranasal Insulin
Given the brain insulin resistance phenotype in AD, restoring insulin signaling is a major therapeutic focus:
| Approach |
Mechanism |
Clinical Status |
| Intranasal insulin |
Direct activation of brain insulin receptors → PI3K/Akt |
Phase 2/3 trials in AD; mixed results — some cognitive benefit in APOE4 non-carriers [12] |
| GLP-1 receptor agonists (liraglutide, semaglutide) |
Insulin sensitization; direct neuroprotection via PI3K/Akt and ERK |
Phase 2/3 trials in AD and PD; liraglutide showed reduced brain atrophy in ELAD trial |
| Metformin |
AMPK activation → mTORC1 inhibition; indirect insulin sensitization |
Epidemiological data suggest reduced AD risk; clinical trials underway |
| Thiazolidinediones (pioglitazone) |
PPARγ agonist; insulin sensitization |
TOMORROW trial in AD prevention; limited efficacy in symptomatic AD |
Direct inhibition of the pathological downstream effector of Akt deficiency:
- Tideglusib: A non-ATP competitive GSK-3β inhibitor tested in Phase 2 trials for AD and PSP. Showed reduction in brain atrophy but limited cognitive benefit
- Lithium: The oldest known GSK-3β inhibitor; epidemiological studies suggest reduced dementia risk with chronic lithium use. Limitations include narrow therapeutic window and renal toxicity [13]
- AZD1080: ATP-competitive GSK-3β inhibitor with good brain penetration; development discontinued
- Rapamycin (sirolimus): mTORC1 inhibitor that induces autophagy; reduces Aβ and tau pathology in multiple AD mouse models. The REACH trial is testing rapamycin for AD prevention [14]
- Everolimus: mTOR inhibitor with better oral bioavailability; preclinical evidence in HD and PD models
- Dual PI3K/mTOR inhibitors: Investigational compounds being evaluated in preclinical neurodegeneration models
¶ BDNF and Neurotrophin-Based Approaches
Restoring physiological PI3K/Akt activation through upstream neurotrophin signaling:
- BDNF gene therapy (AAV-BDNF) for AD — Phase 1 trials
- TrkB agonists: 7,8-dihydroxyflavone (7,8-DHF), LM22A-4
- GDNF delivery for PD — multiple gene therapy trials
graph TD
INSULIN["Insulin / IGF-1"] --> IRS["IRS-1/2"] -->
BDNF2["BDNF / NGF"] --> TRK["TrkB / TrkA"] -->
IRS --> PI3K["PI3K<br/><small>p85/p110</small>"] -->
TRK --> PI3K
PI3K --> PIP3["PIP3"] -->
PTEN["PTEN") -.->|Inhibits| PIP3
PIP3 --> AKT["Akt/PKB<br/><small>Thr308 + Ser473</small>"] -->
AKT --> GSK["GSK-3β<br/><small>Ser9 → INHIBITED</small>"] -->
AKT --> MTOR["mTORC1<br/><small>ACTIVATED</small>"] -->
AKT --> FOXO["FOXO1/3a<br/><small>Nuclear EXCLUSION</small>"] -->
AKT --> BAD2["BAD<br/><small>INACTIVATED</small>"] -->
GSK -->|When active| TAU3["Tau Hyperphosphorylation")
GSK -->|When active| ABETA["Aβ Production ↑"] -->
MTOR -->|Inhibits| AUTOPHAGY["Autophagy")
FOXO -->|When nuclear| APOP2["Pro-apoptotic Genes"] -->
BAD2 -->|When active| MITO2["Mitochondrial Apoptosis"] -->
AUTOPHAGY -->|Impaired| AGGREG["Protein Aggregate<br/>Accumulation"]
style AKT fill:#2ecc71,stroke:#27ae60,color:white
style GSK fill:#e74c3c,stroke:#c0392b,color:white
style MTOR fill:#f39c12,stroke:#e67e22,color:white
- [MAPK/ERK]: ERK and Akt share substrates (BAD, GSK-3β, CREB) and often act synergistically for neuroprotection. However, in cancer biology, cross-inhibition between pathways occurs through negative feedback loops
- AMPK: Energy sensor that antagonizes mTORC1 independently of Akt, allowing autophagy induction without suppressing Akt-mediated survival — a therapeutically desirable dissociation
- [Calcium signaling]: Calmodulin-dependent kinases can activate PI3K, while sustained Ca²⁺ elevation activates calcineurin, which dephosphorylates and inactivates Akt
- [Wnt/β-catenin]: Wnt signaling inhibits GSK-3β through a PI3K-independent mechanism (Dishevelled-mediated sequestration), providing an alternative neuroprotective route
- NF-κB: Akt activates IKKα, promoting NF-κB nuclear translocation. In neurons, NF-κB is generally pro-survival; in glia, it drives neuroinflammation
The study of Pi3K Akt Signaling In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169(3):381-405. DOI
- [Gabbouj S et al. Altered insulin signaling in Alzheimer's Disease brain — special emphasis on PI3K-Akt pathway. Front Neurosci. 2019;13:629. DOI
- [Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 2012;4(9):a011189. DOI
- [Talbot K et al. Demonstrated brain insulin resistance in Alzheimer's Disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316-1338. DOI
- [Zhao WQ et al. amyloid-beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008;22(1):246-260. DOI
- [Beurel E et al. Glycogen synthase kinase-3 ([GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114-131. DOI
- [Heras-Sandoval D et al. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014;26(12):2694-2701. DOI
- [Chen Z, Bhatt DK. The role of PI3K signaling pathway in Alzheimer's Disease. Front Aging Neurosci. 2024;16:1459025. DOI
- [Rocha VP et al. Astrocyte and microglial disparities in PI3K/AKT signaling: implications for Parkinson's Disease inflammation. Sci Arch. 2024;5(2):41-52. DOI
- [Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125(1):25-32. DOI
- [Norambuena A et al. The PI3K/Akt signaling axis in Alzheimer's Disease: a valuable target to stimulate or suppress? Cell Stress Chaperones. 2021;26(5):871-887. DOI
- [Craft S et al. Intranasal insulin therapy for Alzheimer's Disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69(1):29-38. DOI
- [Forlenza OV et al. Does lithium prevent Alzheimer's Disease? Drugs Aging. 2012;29(5):335-342. DOI
- [Kaeberlein M, Galvan V. Rapamycin and Alzheimer's Disease: time for a clinical trial? Sci Transl Med. 2019;11(476):eaar4289. DOI
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
14 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
67% |
| Mechanistic Completeness |
50% |
Overall Confidence: 46%